Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Omeros Co. (NASDAQ:OMER - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $22.50.

OMER has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Omeros in a research note on Thursday, November 14th. Rodman & Renshaw assumed coverage on Omeros in a report on Thursday, November 14th. They set a "buy" rating and a $9.00 price objective on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research note on Thursday. D. Boral Capital assumed coverage on shares of Omeros in a research note on Monday. They set a "buy" rating and a $36.00 price target on the stock. Finally, RODMAN&RENSHAW upgraded shares of Omeros to a "strong-buy" rating in a report on Thursday, November 14th.

Hedge Funds Weigh In On Omeros

A number of large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its holdings in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 7,016 shares during the last quarter. MML Investors Services LLC grew its stake in shares of Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 3,000 shares during the last quarter. SPC Financial Inc. bought a new stake in shares of Omeros in the third quarter worth about $77,000. SG Americas Securities LLC purchased a new position in Omeros during the 3rd quarter valued at about $80,000. Finally, AQR Capital Management LLC bought a new position in Omeros during the 2nd quarter valued at approximately $105,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Stock Down 1.9 %

Shares of NASDAQ OMER traded down $0.20 during mid-day trading on Monday, reaching $10.11. 950,691 shares of the company were exchanged, compared to its average volume of 552,035. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The company's 50 day moving average price is $7.09 and its 200 day moving average price is $5.20. The stock has a market capitalization of $585.87 million, a PE ratio of -4.38 and a beta of 1.97.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.